Skip to content

Application of binaural beat music and esketamine in modified electroconvulsive therapy for depression

Application of binaural beat music and esketamine in modified electroconvulsive therapy for depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094873
Enrollment
Unknown
Registered
2024-12-30
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Group B0K0:Blank sound file + normal saline
Group B1K0:Binaural beat music + normal saline
Group B0K1:Blank sound file + esketamine
Group B1K1:Binaural beat music + esketamine

Sponsors

The First Affiliated Hospital of Chongqing Medical University, Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 59 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with major depressive disorder who need to be hospitalized for MECT treatment; (2) age 19-59 years; (3) no previous serious comorbidities; (4) American Society of Anesthesiologists (ASA) grade I.-II; (5) Body mass index 18.5-30 kg/m^2; (6) The patient and/or his/her guardian understand and agree, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Combined with serious medical and/or surgical diseases, such as intracranial electrode clips or cardiac pacemakers, etc.; (2) Combined with other psychiatric diseases, such as schizophrenia, etc.; (3) Suffering from diseases or conditions that cannot be completed or affect the efficacy assessment, such as cognitive dysfunction, illiteracy, mental retardation, etc.; (4) There are contraindications to anesthesia or electroconvulsive; (5) Hypertension, risk of intracranial hypertension, hyperthyroidism, severe heart disease or any contraindication to the use of ketamine; (6) Allergy to (es) ketamine; (7) (es) ketamine, or other drug or alcohol dependence; (8) The previous (es) ketamine test was invalid or there were serious adverse reactions; (9) Ineffective or serious adverse reactions of previous MECT therapy; (10) Pregnant women; (11) Participated in other clinical trials within the past 1 year.

Design outcomes

Primary

MeasureTime frame
Response rate after MECT treatment;

Secondary

MeasureTime frame
Depression remission rate after MECT treatment;Remission rate of suicidal ideation;Psychotic symptoms associated with depression;Cognitive function;Parameters of electroconvulsive therapy;Perianesthetic vital signs and anesthesia related data;Blood biochemical index;

Countries

China

Contacts

Public ContactJie Luo

The First Affiliated Hospital of Chongqing Medical University

jieluo@hospital.cqmu.edu.cn+86 157 3007 6532

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026